The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
ImmunoPrecise Announces R&D Positive Results Using the OmniAb Platform
Aug. 29, 2017 10:12AM PST
Biotech InvestingImmunoPrecise Antibodies announced it is now an approved contract research organization for the development of human monoclonal antibodies with the OmniAb platform.
ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced it is now an approved contract research organization for the development of human monoclonal antibodies with the OmniAb platform.
As quoted in the press release:
The OmniAb platform consists of the OmniRat, OmniMouse and OmniFlic transgenic rodents. These rodents are bred to produce highly diversified antibody repertoires for the discovery of fully human antibodies with potentially superior therapeutic efficacy and reduced immunogenicity. The OmniAb platform is owned by Ligand Pharmaceuticals.
ImmunoPrecise Antibodies has now completed two research and development projects, which allowed the Company to test and optimize its unique and proprietary methodologies, including the Rapid Prime immunization protocol.
Click here to read the full press release.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.